Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 14INDUSTRY 11OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 64Neoplasms 45Colorectal Neoplasms 30Uterine Cervical Neoplasms 29Carcinoma, Hepatocellular 23Stomach Neoplasms 19Prostatic Neoplasms 19Carcinoma, Non-Small-Cell Lung 19Ovarian Neoplasms 17Lung Neoplasms 15Esophageal Neoplasms 13Pancreatic Neoplasms 12Multiple Myeloma 12Motor Activity 10Endometrial Neoplasms 10Urinary Bladder Neoplasms 9Colonic Neoplasms 9Recurrence 8Rectal Neoplasms 8Lymphoma, Follicular 8Melanoma 7Lymphoma 7Liver Neoplasms 7Hematologic Neoplasms 7Carcinoma, Ovarian Epithelial 7Triple Negative Breast Neoplasms 6Sleep Initiation and Maintenance Disorders 6Sarcopenia 6Neuroendocrine Tumors 6Leukemia 6

Interventions

Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Diabetes Mellitus, Insulin-Dependent, 12 × 1 year × Clear all
NCT07128251 2025-08-17

A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC)

Anhui Provincial Hospital

Phase 2 Not yet recruiting
47 enrolled
Gastrointestinal

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡